comparemela.com

Latest Breaking News On - நதி ஆய்வகங்கள் - Page 7 : comparemela.com

Small modular reactor project at the Chalk River Laboratories moves to formal licence review with CNSC

Small modular reactor project at the Chalk River Laboratories moves to formal licence review with CNSC
pembrokeobserver.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pembrokeobserver.com Daily Mail and Mail on Sunday newspapers.

Small modular reactor project at the Chalk River Laboratories moves to formal licence review with CNSC

Small modular reactor project at the Chalk River Laboratories moves to formal licence review with CNSC
standard-freeholder.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from standard-freeholder.com Daily Mail and Mail on Sunday newspapers.

Small modular reactor project at the Chalk River Laboratories moves to formal licence review with CNSC

Small modular reactor project at the Chalk River Laboratories moves to formal licence review with CNSC
recorder.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from recorder.ca Daily Mail and Mail on Sunday newspapers.

Charles River lays out $293M to snap up viral vector specialist Vigene, its 2nd M&A deal this year

Charles River Laboratories will pay $292.5 million in cash for gene therapy CDMO Vigene Biosciences. The move will add viral vector and plasmid DNA manufacturing to Charles River’s cell and gene repertoire boosting its presence in a CMDO market valued at $2.5 billion globally and growing, the company said.

The Worldwide Immuno-Oncology Assays Industry is Projected to Reach $7 9 Billion by 2026 at a CAGR of 12 5% from 2021

Share this article Share this article ResearchAndMarkets.com s offering. The global immuno-oncology assays market is projected to reach USD 7.9 billion by 2026 from USD 4.4 billion in 2021, at a CAGR of 12.5% during the forecast period. Market growth is driven by factors such as the growing significance of companion diagnostics in drug development and rising incidence of cancer and growing adoption of targeted therapies. On the other hand, the requirement of high capital investments and low cost-benefit ratio and the unfavorable regulatory and reimbursement scenario are the major factors hampering the growth of this market. The consumables segment accounted for the highest growth rate in the immuno-oncology assays market, by product & service, during the forecast period

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.